Ivabradine for rate control in atrial fibrillation.

[1]  M. Turakhia,et al.  Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. , 2014, Journal of the American College of Cardiology.

[2]  D. Logeart,et al.  Might ivabradine be useful in permanent atrial fibrillation? , 2014, International journal of cardiology.

[3]  R. Verrier,et al.  Inhibition of I(f) in the atrioventricular node as a mechanism for dronedarone's reduction in ventricular rate during atrial fibrillation. , 2013, Heart rhythm.

[4]  R. Charnigo,et al.  Increased mortality among patients taking digoxin--analysis from the AFFIRM study. , 2013, European heart journal.

[5]  A. Ludwig,et al.  Novel insights into the distribution of cardiac HCN channels: an expression study in the mouse heart. , 2011, Journal of molecular and cellular cardiology.

[6]  M R Boyett,et al.  Molecular architecture of the human specialised atrioventricular conduction axis. , 2011, Journal of molecular and cellular cardiology.

[7]  Michael Böhm,et al.  Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study , 2010, The Lancet.

[8]  Yan Ou,et al.  Expression of key ion channels in the rat cardiac conduction system by laser capture microdissection and quantitative real‐time PCR , 2010, Experimental physiology.

[9]  Jean-Claude Tardif,et al.  Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. , 2005, European heart journal.